Explore the words cloud of the VulneraBAP1 project. It provides you a very rough idea of what is the project "VulneraBAP1" about.
The following table provides information about the project.
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
|Coordinator Country||Germany [DE]|
|Total cost||171˙460 €|
|EC max contribution||171˙460 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2018-07-01 to 2020-06-30|
Take a look of project's partnership.
|1||DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG||DE (HEIDELBERG)||coordinator||171˙460.00|
Kidney cancer is among the ten most prevalent cancers arising in Western countries, with clear-cell renal cell carcinoma (ccRCC) being the most frequent subtype (75%). About 30% of ccRCC patients present with metastatic disease at diagnosis, and another 30% will develop metastases after surgery. When metastatic, ccRCC remains largely incurable.
I recently discovered that the tumor suppressor BAP1 (BRCA1-associated protein 1) is inactivated in 15% of ccRCCs (Peña-Llopis et al. Nat. Genet. 2012). Notably, I found that mutations in BAP1 are mutually exclusive with mutations of the tumor suppressor gene PBRM1, and loss of BAP1 was associated with higher tumor grade, activation of mTORC1, and poorer overall patient survival, whereas tumors with PBRM1 loss were associated with lower tumor grade and better overall survival. This first molecular genetic classification of ccRCC may have tangible clinical implications, since tumors with BAP1 loss display in general more aggressive pathological features and are more prone to metastasize. However, the molecular mechanism through which BAP1 loss induces metastasis and tumor aggressiveness remains elusive.
In this study, I aim to investigate the molecular mechanism of repression of a miRNA cluster involved in metastasis by BAP1 and identify therapeutic opportunities. Specifically, I will (1) supervise a PhD student (supported by a grant I was recently been awarded) in the identification and characterization of the BAP1 protein complex that binds at the miRNA cluster promoter; and (2) I will uncover the genetic vulnerabilities of BAP1 loss by a synthetic lethality strategy. These studies will facilitate attainment of my long term career goal to become a group leader and a fully independent investigator.
|year||authors and title||journal||last update|
Max Fleischmann, Daniel Martin, Samuel PeÃ±a-Llopis, Julius Oppermann, Jens von der GrÃ¼n, Markus Diefenhardt, Georgios Chatzikonstantinou, Emmanouil Fokas, Claus RÃ¶del, Klaus Strebhardt, Sven Becker, Franz RÃ¶del, Nikolaos Tselis
Association of Polo-Like Kinase 3 and PhosphoT273 Caspase 8 Levels With Disease-Related Outcomes Among Cervical Squamous Cell Carcinoma Patients Treated With Chemoradiation and Brachytherapy
published pages: , ISSN: 2234-943X, DOI: 10.3389/fonc.2019.00742
|Frontiers in Oncology 9||2020-01-29|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VULNERABAP1" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "VULNERABAP1" are provided by the European Opendata Portal: CORDIS opendata.